Questcor Pharmaceuticals Inc  

(Public, NASDAQ:QCOR)   Watch this stock  
Find more results for QCOR
34.86
-0.43 (-1.22%)
May 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 34.02 - 35.42
52 week 17.25 - 58.91
Open 35.33
Vol / Avg. 1.37M/1.98M
Mkt cap 2.08B
P/E 10.79
Div/yield 0.25/2.87
EPS 3.23
Shares 59.55M
Beta 0.74
Inst. own 110%
Jul 24, 2013
Q2 2013 Questcor Pharmaceuticals, Inc. Earnings Release Add to calendar
May 24, 2013
Questcor Pharmaceuticals, Inc. Annual Shareholder Meeting
May 14, 2013
Questcor Pharmaceuticals, Inc. at Bank of America Merrill Lynch Health Care Conference
Apr 30, 2013
Q1 2013 Questcor Pharmaceuticals, Inc. Earnings Conference Call
Apr 29, 2013
Q1 2013 Questcor Pharmaceuticals, Inc. Earnings Release
Feb 26, 2013
Q4 2012 Questcor Pharmaceuticals, Inc. Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 28.91% 38.81%
Operating margin 43.18% 58.22%
EBITD margin - 58.72%
Return on average assets 52.39% 74.84%
Return on average equity 87.65% 103.59%
Employees 557 -
Carbon Disclosure Rating - -

Address

Suite D, 1300 North Kellogg Drive
ANAHEIM HILLS, CA 92807
United States - Map
+1-714-7864200 (Phone)
+1-714-7894229 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Questcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. The Company is focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Its primary product is H.P. Acthar Gel (repository corticotropin injection), or Acthar, an injectable drug that is approved by the United States food and drug administration (FDA), for the treatment of 19 indications. Its research and development program is focused on: the evaluation of the use of Acthar for certain on-label indications; the investigation of other potential uses of Acthar for indications not FDA approved; and the expansion of its understanding of how Acthar works in the human body (pharmacology), and ultimately, its mechanisms of action in the disease states for which it is used, or may be used in the future. The Company sells Doral to pharmaceutical wholesalers, which resell Doral primarily to retail pharmacies and hospitals.

Officers and directors

Virgil D. Thompson Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Don M. Bailey President, Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Michael H. Mulroy Chief Financial Officer, Senior Vice President, General Counsel, Corporate Secretary
Age: 46
Bio & Compensation  - Reuters
Stephen L. Cartt Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
David J. Medeiros Executive Vice President, Chief Technical Officer
Age: 61
Bio & Compensation  - Reuters
David Young Ph.D. Chief Scientific Officer
Age: 60
Bio & Compensation  - Reuters
Mitchell J. Blutt M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
Neal C. Bradsher Independent Director
Age: 46
Bio & Compensation  - Reuters
Stephen C. Farrell CPA Independent Director
Bio & Compensation  - Reuters
Louis E. Silverman Independent Director
Age: 53
Bio & Compensation  - Reuters